Group_1_TA_Agata_Kieliszek_Presentation_1 "Immune responses against SARS-CoV-2";
Group_1_TA_Agata_Kieliszek_Presentation_2 "Immune responses against SARS-CoV-2";
Group_2_TA_Sansi_Xing "Pathogenesis and transmission of SARS-CoV-2";
Group_2_TA_Sansi_Xing "Transgenic Mouse model of SARS-CoV-2 pathogenesis and transmission";
Group_3_TA_Agata_Kieliszek "Therapeutic targeting of SARS-CoV-2";
Group_3_TA_Agata_Kieliszek_Presentation_2 "Therapeutic Targeting of SARS-CoV-2";
Group_4_TA_Sansi_Xing "Vaccine treatment of SARS-CoV-2";
Group_4_TA_Sansi_Xing_Presentation_2 "Vaccine treatment of SARS-CoV-2";
Group_5_TA_Agata_Kieliszek "Stem cell models and/or therapies for SARS-CoV-2";
Group_5_TA_Agata_Kieliszek_Presentation_2 "Stem cell models and/or therapies for SARS-CoV-2";
Group_6_TA_Sansi_Xing "Diagnostics of SARS-CoV-2"
Group_6_TA_Sansi_Xing_Presentation_2 "CRISPR-Cas12-based detection of SARS-CoV-2"
